CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)

Trial Profile

CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Metformin (Primary)
  • Indications Cardiovascular disorders; Prediabetic-state
  • Focus Therapeutic Use
  • Acronyms VA-IMPACT
  • Most Recent Events

    • 25 May 2017 Planned End Date changed from 1 Oct 2023 to 31 Mar 2024.
    • 25 May 2017 Planned primary completion date changed from 1 Oct 2023 to 31 Mar 2023.
    • 25 May 2017 Planned initiation date changed from 1 May 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top